- Ventyx Biosciences press release ( NASDAQ: VTYX ): Q2 GAAP EPS of -$0.39 beats by $0.06 .
- VTX958, our allosteric TYK2 inhibitor, demonstrated an excellent safety profile and class-leading target coverage in Phase 1 trial
- Cash, cash equivalents and marketable securities of $258.4 million as of June 30, 2022, expected to support operations into the first half of 2024
- Ventyx to host conference call and webcast today at 4:30 PM ET to discuss topline results from the Phase 1 trial of VTX958
For further details see:
Ventyx Biosciences GAAP EPS of -$0.39 beats by $0.06